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Purpose: Cardiac dysfunction and hyperdynamic systemic
circulation may be present in patients with cirrhosis. The
purpose of this study was to identify relations between plasma
levels of N-terminal-proBNP (NT-proBNP), reflecting early
ventricular dysfunction, and the severity of liver disease and
cardiac dysfunction in cirrhotic patients. Materials and
Methods: Sixty-three cirrhotic patients and 15 controls (group
1) were enrolled in this study. Plasma levels of NT-proBNP
were determined in echocardiographically examined patients,
which were allocated to 1 of 3 groups according to Child-Pugh
classification or into 2 groups, i.e., a compensated group
without ascites (group 2) and decompensated group with
ascites (group 3). Results: Plasma NT-proBNP levels were
significantly higher in cirrhotic patients (groups 2 and 3) than
in age-matched controls (155.9 and 198.3 vs. 40.3 pg/mL,
respectively, p < 0.05). NT-proBNP levels were significantly
increased in Child class C patients than in classes B and A
(250.0 vs. 168.6 and 119.6 pg/mL, respectively, p < 0.05). Left
atrial dimension, wall thickness of left ventricle, and EF or
E/E' were significantly increased, and EDT was prolonged in
cirrhotic patients than in controls. Increased LVMI and
decreased E/A ratio were noted in the group of patients with
ascites as compared with the other groups. Conclusion: Plasma
NT-proBNP levels were high in cirrhotic patients and are
likely to be related to the severity of disease. Advanced
cirrhosis is associated with advanced cardiac dysfunction, and
NT-proBNP levels has predictive value for concomitant
cardiac dysfunction and cirrhosis progression.
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INTRODUCTION
Systemic circulation in patients with cirrhosis is
hyperdynamic and is characterized by an increased
heart rate and cardiac output and reduced
systemic vascular resistance with normal or
decreased arterial blood pressure.
1-3 In cirrhotic
patients, cardiac output is increased at rest, and
it has been assumed that systolic function is
normal or even supranormal.
4,5 However, many
cirrhotic patients present with dyspnea, fluid
retention, and limited exercise capacity.
6,7 As a
solution to these clinical manifestions, the newly
introduced clinical entity, formerly known as
latent alcoholic cardiomyopathy, cirrhotic cardio-
myopathy, reflects a condition with defective
myocardial contractility under physical and
pharmacological strain.
8,9 Although this cardiac
dysfunction due to hepatic failure has not yet
been finally classified and the mechanisms are not
fully understood, early detection of this condition
is crucial. Several studies have shown increased
plasma levels of brain natriuretic peptide (BNP)
and NT-proBNP in some patients with cirrhosis,
and these findings may suggest cardiac dysfunc-
tion.
10-12 NT-proBNP has recently suggested been
to be a even better indicator of early cardiac
dysfunction than BNP because of its stability and
longer biological half-life.
13-15 However, until now
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very few studies have assessed the levels of
plasma NT-proBNP in cirrhotic patients, therefore,
the exact role of NT-proBNP in the noninvasive
diagnosis of cardiac dysfunction in cirrhotic
patients remains to be fully clarified. Consequently,
this study was undertaken to examine relationships
between plasma levels of NT-proBNP and
severities of liver disease and cardiac dysfunction,
further investigate cardiac structures and
functions by echocardiography and assess their
correlations with disease severity and cardiac
dysfunction in cirrhotic patients.
MATERIALS AND METHODS
Study population
From March 2004 to October 2005, 63 cirrhotic
patients were enrolled in this study. They con-
sisted of 40 men and 23 women with a mean age
of 55.8 ± 10.1 years (range, 40 - 71 years). Diagnoses
were based on established clinical, biochemical,
and ultrasonography criteria. The cause of cirrhosis
was post-hepatic cirrhosis due to hepatitis B virus
infection in 32 patients, hepatitis C virus infection
in 6, alcoholic in 19, autoimmune in 2, and crypto-
genic in 4. According to Child-Pugh classification,
16 patients were in class A, 29 in class B, and 18
in class C. The age-matched control group (group
1) comprised of 15 healthy adults with a mean age
of 52.9 ± 10.5 years (range, 41 - 67 years). We
divided the cirrhotic patients into a compensated
group without ascites (group 2, pre-ascitic, n = 28)
and a decompensated group with ascites (group
3, ascitic, n = 35). Patients in group 3 had received
diuretic therapy along with a less strict dietary
salt restriction (440 mmol sodium per day) but
additional cardiovascular medication, including
beta blockers, was not prescribed for any of these
patients. Seventeen patients had a hepatic en-
cephalopathy history. Exclusion criteria for study
subjects were presence of cardiac, pulmonary, and
renal diseases; hypertension; and other major
organic diseases. All patients and controls received
a normal cardiac physical examination, chest
X-ray, and electrocardiography (ECG). The base-
line clinical and biochemical characteristics of the
patients and controls are summarized in Table 1.
Study protocol
Blood was drawn from a forearm vein after at
least 10 minutes of resting supine, collected in
standard sampling tubes for NT-proBNP analysis,
and in appropriate tubes for other laboratory
Table 1. Baseline Clinical and Biochemical Characteristics of the Cirrhotic Patients and Controls
Parameter Controls (n = 15)
Cirrhotic group
Pre-ascitic (n = 28) Ascitic (n = 35)
Age (yrs) 52.9 ± 10.5 56.7 ± 9.2 54.9 ± 11.0
Gender (M : F) 6 : 9 18 : 10 22 : 13
Hb (g/L) 13.7 ± 1.5 10.8 ± 2.2* 10.3 ± 2.0*
PT (INR) 1.0 ± 0.1 1.3 ± 0.2* 1.6 ± 0.3*
Album (g/L) 4.1 ± 0.4 3.4 ± 0.6* 2.9 ± 0.4*
Total bilirubin (mg/dL) 0.6 ± 0.1 3.1 ± 2.8* 4.7 ± 4.1*
Na 143.7 ± 2.4 138.4 ± 4.6* 136.5 ± 5.7*
K 4.3 ± 0.9 4.0 ± 0.7 4.3 ± 0.6
Cr 1.0 ± 0.2 1.0 ± 0.3 1.1 ± 0.3
M, male; F, female; Hb, hemoglobin; PT, prothrombin time; Cr, creatinine.
*p < 0.05, compared with control. p < 0.05, compared with preascitic group.
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determinations. A complete blood count, pro-
thrombin time [PT, as reflected by the interna-
tional normalized ratio (INR)], and liver and
renal function tests were performed using
standard laboratory automated techniques.
Plasma NT-proBNP levels were determined using
a commercially available immunoassay based on
the sandwich technique (Elecsys proBNP, Roche
Diagnostics); its lower and upper limits of
detection were 5 pg and 35,000 pg/mL, respec-
tively. This is a rapid assay with a test time of
approximately 18 minutes for a single sample,
and test results were calculated automatically. All
patients and controls were studied by M-mode,
2-dimensional, and Doppler echocardiography
via transthoracic approach. Cardiac dimensions
and left ventricular hypertrophy were evaluated
by measuring echocardiographic parameters,
including interventricular septum thickness in
diastole (IVSd), left ventricular posterior wall
thickness in diastole (LVPWd), left ventricular
end-diastolic diameter (LVEDD), left ventricular
end-systolic diameter (LVESD), left ventricular
mass index (LVMI), and left atrial diameter
(LAD). Systolic pump function of the left
ventricle (LV) was evaluated by ejection fraction
(EF). Diastolic function of the left ventricle was
evaluated by the peak filling velocity of E (E) and
A waves (A) of Doppler mitral valve inflow
velocities, E/A ratio, E wave deceleration time
(EDT), mitral valve annular velocities (E') by
Doppler tissue imaging, and E'/E. In addition,
LV-Tei index was used as a parameter of
combined systolic and diastolic myocardial
performance of the LV.
Statistical analysis
All statistical evaluations were performed using
SPSS statistical package (version 12.0, SPSS,
Chicago, IL, USA). Results are expressed as means
± SD for raw values. Kruskal-Wallis test was used
for assessment of statistical differences in baseline
characteristics, biochemical or echocardiographic
parameters, and plasma NT-pro BNP levels
between groups or Child classes. The p < 0.05
were considered statistically significant.
Table 2. Echocardiographic Parameters in Cirrhotic Patients and Controls
Parameter Controls (n = 15)
Cirrhotic group
Pre-ascitic (n = 28) Ascitic (n = 35)
EF (%) 59.3 ± 6.2 70.5 ± 7.8* 71.2 ± 7.0*
LAD (mm) 35.1 ± 7.4 39.7 ± 4.8* 40.5 ± 4.6*
LVEDD (mm) 46.5 ± 2.6 49.0 ± 3.1 48.2 ± 4.6
IVSd (mm) 8.7 ± 1.5 10.1 ± 2.0* 10.1 ± 1.7*
LVPWd (mm) 8.2 ± 1.7 9.2 ± 1.8* 9.6 ± 1.2*
LVMI (g/m
2) 102.8 ± 23.5 110.2 ± 23.1 123.5 ± 22.5*
E/A ratio 1.2 ± 0.4 1.0 ± 0.4 0.9 ± 0.3*
E/E' 8.8 ± 1.1 10.5 ± 1.9* 11.8 ± 2.3*
EDT(msec) 206.0 ± 35.3 254.3 ± 60.8* 271.1 ± 53.7*
LV Tei index 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
EF, ejection fraction of left ventricle; LAD, left atrium diameter; LVEDD, left ventricular end-diastolic diameter; IVSd, interventricular
septum thickness in diastole; LVPWd, left ventricular posterior wall thickness in diastole; LVMI, left ventricular mass index; E/A
ratio, ratio of velocity of E wave to velocity of A wave of Doppler mitral valve inflow; EDT, deceleration time of E wave; E',
mitral valve annular velocities.
*p < 0.05, compared with control. p < 0.05, compared with preascitic group.Jeong Joo Woo, et al.
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RESULTS
Echocardiographic parameters according to the
decompensation component of cirrhosis are given
in Table 2. Left atria were significantly enlarged
in cirrhotic patients (groups 2 and 3) compared
with the group (group 1) of normal controls (39.7
± 4.8 mm in group 2 and 40.5 ± 4.6 mm in group
3 vs. 35.1 ± 7.4 mm in group 1) and wall thickness
of LV was increased in cirrhotic patients
compared with controls (10.1 ± 2.0 mm or 9.2 ± 1.8
mm in group 2 and 10.1 ± 1.7 mm or 9.6 ± 1.2 mm
in group 3 vs. 8.7 ± 1.5 mm or 8.2 ± 1.7 mm in
group 1, IVSd or LVPWd in each group, p < 0.05).
EF or E/E' was also increased and EDT was
prolonged in patients with cirrhosis vs controls
(70.5 ± 7.8 % or 10.5 ± 1.9 or 254.3 ± 60.8 msec in
group 2 and 71.2 ± 7.0 % or 11.8 ± 2.3 or 271.1 ±
53.7 msec in group 3 vs. 59.3 ± 6.2 % or 8.8 ± 1.1
or 206.0 ± 35.3 msec in group 1, respectively, p <
0.05). On the other hand, no statistically
significant differences were observed for LVEDD
and LV-Tei index between groups 1, 2, and 3.
Increased LVMI and decreased E/A ratio were
noted in the group of patients with ascites
compared with the other groups (123.5 ± 22.5
g/m
2 or 0.9 ± 0.3 in group 3 vs. 110.2 ± 23.1 g/m
2
or 1.0 ± 0.4 in group 2 and 102.8 ± 23.5 g/m
2 or 1.2
± 0.4 in group 1, respectively, p < 0.05). Plasma
NT-proBNP levels were significantly higher in
cirrhotic patients than in normal controls (155.9 ±
69.8 pg/mL in group 2 and 198.3 ± 146.7 pg/mL
in group 3 vs. 40.3 ± 13.6 pg/mL in group 1,
respectively, p < 0.05), but no significant NT-
proBNP level difference was observed between
groups 2 and 3 (p > 0.05; Fig. 1). When patients
were grouped according to Child-Pugh classifi-
cation, plasma NT-proBNP levels were signifi-
cantly higher in Child class C than in classes B
and A, and in controls (250.0 ± 176.6 pg/ mL in
Child class C vs. 168.6 ± 71.3 pg/mL in Child class
B, 119.6 ± 67.3 pg/mL in Child class A, and 40.3
± 13.6 pg/mL in controls, respectively, p < 0.05;
Fig. 2), and no significant NT-proBNP level
difference was observed between Child classes B
and A (p > 0.05).
DISCUSSION
Cirrhosis is associated with many cardio-
vascular changes or abnormalities, including
hyperdynamic circulation, portal hypertension,
hepatopulmonary syndrome, and hepatorenal
syndrome. The main change of cardiovascular
function in cirrhotic patients, i.e., a hyperdynamic
circulation, as manifested by increased cardiac
output and decreased arterial pressure, has been
recognized for a long time.
1-3 Although it tends to
be assumed that cardiac contractile function is
normal or even supranormal due to the presence
of increased cardiac output at rest, many cirrhotic
Fig. 1. Plasma NT-proBNP levels in controls and cirrhotic
patients who were divided into a compensated group
without ascites (pre-ascitic) and a decompensated group
with ascites (ascitic). NS, no significant differences.
Fig. 2. Plasma NT-proBNP levels in controls and cirrhotic
patients grouped as class A, B, and C according to child-
pugh classification. NS, no significant differences.NT-proBNP and the Evaluation of Cardiac Dysfunction and Severity of Disease in Cirrhotic Patients
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patients present with clinical manifestations that
are suggestive of early cardiac dysfunction or
overt heart failure.
2,5-7 Thus, to consider cardio-
vascular changes from a functional point of view,
the heart in cirrhosis is both hyperdynamic and
dysfunctional. For many years, it has been known
that the performance of LV is usually reduced by
stimuli such as drugs or exercise in alcoholic heart
muscle disease or alcoholic cardiomyopathy,
which was presented by some studies of cardiac
function in patients with alcoholic cirrhosis.
16,17
Depressed contractile response to physiologic or
pathophysiologic stimuli has recently been
referred to as cirrhotic cardiomyopathy, a clinical
entity which is clinically and pathophysiologically
different from alcoholic heart muscle disease.
4,8
On the other hand, cirrhotic cardiomyopathy
includes compound changes in increased cardiac
output related to normal or increased systolic
performance without stimuli at rest, but depressed
contractile response to various strain, decreased
beta-adrenergic receptor function, postreceptor
dysfunction, defective excitation contraction
coupling, and conductance abnormalities in some
patients.
9,19 Therefore, in patients with all forms of
cirrhosis, clinically significant cardiac dysfunction
and latent heart failure associated with impaired
cardiac contractility may be outcome when preload
or afterload increased. Since heart failure is
characterized by complicated cardiorenal, hemo-
dynamic, and neurohormonal alterations, infor-
mation on numerous variables is required. For
instance, clinical status, exercise capacity, hemo-
dynamic variables, echocardiographic parameters,
several markers of neurohumoral activation, and
biochemical markers of end-organ dysfunction
might be considered to assess and monitor
patients with heart failure.
20,21 In general, structural
or functional changes in the cirrhotic heart are
easily evaluated by M-mode, 2-dimensional, and
Doppler echocardiographic studies via the trans-
thoracic approach.
18,22-25 Main structural changes
in the cirrhotic heart are observed in the left heart
and include dilatation of the left atrium and
hypertrophy or dilatation of the left ventricle. In
cirrhotic patients, systolic function is normal or
even supranormal at rest without a stimulus but
cardiac contractile function in response to strains
attenuates these functions compared with healthy
controls. Diastolic dysfunction in the cirrhotic
heart appears to be more prevalent than systolic
dysfunction, therefore, echocardiography may
reveal abnormal diastolic function under circum-
stances without strain or even at rest.
22-25 In the
present study, left atrial enlargement, increased
wall thickness and EF of the left ventricle, and
E/E' of mitral annulus velocity were noted in
cirrhotic patients as compared with controls. In
addition, increased LVMI and decreased E/A
ratio were noted in the group of ascitic patients
as compared with pre-ascitic patients or healthy
controls. On the other hand, no statistically
significant difference was observed between these
three groups in terms of LVEDD or LV-Tei index.
These findings are similar to the structural and
functional changes reported by previous studies.
It is expected that E/E' measurements make up
for the weak points of Doppler transmitral inflow
measurement, and that E/E' may be used as a
reliable marker of diastolic dysfunction in
cirrhotic patients. Additionally, more prevalent
left ventricular hypertrophy and relaxation
abnormality in decompensated patients with more
advanced cirrhosis suggest that advanced cirrhosis
is associated with more advanced cardiac
dysfunction. Meanwhile, the natriuretic peptides
have recently been highlighted as major markers
for the diagnosis, severity, and prognosis of heart
failure, whereas other conventional cardiac
function tests are time consuming and often do
not correlate well with symptomatic changes in
patients' conditions. B-type natriuretic peptide
(BNP) is a neurohormone synthesized along with
atrial natriuretic peptide (ANP) in cardiac
ventricles. BNP is released as preproBNP and then
enzymatically cleaved to NT-proBNP and BNP,
depending on ventricular myocyte stretching and
volume overload.
15 In cases of heart failure,
ventricular BNP production is markedly elevated,
and circulating BNP concentrations are consistently
elevated in untreated heart failure.
26 Accordingly,
blood measurements of BNP and NT-proBNP
have been found to be of diagnostic value in
congestive heart failure (CHF) related to CHF
severity. Moreover, they could be used for
adjusting treatment and have been shown to be
powerful prognostic markers in both chronic and
acute heart failure, independent of standardJeong Joo Woo, et al.
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echocardiographic parameters.
15,27-30 However,
NT-proBNP is influenced by age and the age-
related normal decline in glomerular filtration
rate, therefore 2 cutoff points must be used; i.e.,
NT-proBNP > 125 pg/mL in patients younger
than 75 years and > 450 pg/mL in patients older
than 75 years.
15 Despite a close relationship between
age and renal function, NT-proBNP has recently
been suggested to be an even better marker of
early cardiac dysfunction or heart failure than
BNP because it is more stable and less sensitive
to rapid fluctuations caused by short-term
secretion stimuli due to its appreciably longer
biological half-life.
13-15 A study by Henriksen et
al.
12 showed that circulating proBNP concentra-
tions are significantly increased in patients with
advanced cirrhosis and that they are closely
related to BNP concentrations, however, no signs
of reduced hepatic degradation of proBNP or of
BNP are present in patients with cirrhosis,
suggesting that elevated levels of proBNP and
BNP are related to markers of cirrhotic severity
and indicate the presence of cardiac dysfunction
in advanced cirrhosis. In the present study,
plasma NT-proBNP levels were found to be
significantly higher in cirrhotic patients than in
controls, and also higher in Child class C patients
than in classes B and A or controls. Importantly,
a significant correlation was observed between
NT-proBNP and Child class, suggesting that
plasma NT-proBNP levels are likely to be related
to the severity of cirrhosis. Ascites is 1 of the
parameters of Child-Pugh classification that indi-
cates liver disease severity. Thus, progressive
increases in the ascites ratios in cirrhotic patients
from Child classes A, B, and C is expected,
however, no significant plasma NT-proBNP level
differences were observed between pre-ascitic and
ascitic patients in the present study. This result
represents 1 of the limitations of this study, which
may be attributable to diuretic therapy before
blood sampling in cirrhotic patients with ascites.
De Lemos et al.
30 have advocated that the net
effect of beta-blockers and diuretics is often to
reduce BNP concentration. Therefore, further
experimental and clinical research is needed to
assess the significance of nonspecific and specific
therapies influencing preload and afterload,
including drug therapy with diuretics, beta-
blockers, and angiotensin inhibitors. Another
limitation of this study is the relatively small
study population and short follow-up period. The
inclusion of a larger population and long-term
follow-up may be necessary. In conclusion, the
present study shows that plasma NT-proBNP
levels, LAD and LVMI, E/A ratio, EDT, and E/E'
may be reliable indicators of the extent of cardiac
abnormalities in cirrhotic patients. After all,
increased levels of NT-proBNP have significant
clinical implications in patients with all forms of
cirrhosis because it was found to be related to
disease severity. Thus, it may be suggested that
cardiac dysfunction is related to an increased
plasma NT-proBNP levels, which in turn is more
prominent in severe disease, and that NT-proBNP
has predictive value in cases of concomitant
cardiac dysfunction and cirrhotic progression.
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